CCCC: C4 Therapeutics, Inc.
Performance
CCCC +34.62%
Watchlist
Select an item
Summary
CCCC at a glance
CCCC returned +34.62% over the past year and -41.20% a year over five years. Its worst drop in that year was -44.11%, smaller than 31% of stocks on Redstone, and its Sharpe ratio of 0.72 beats 61% of stocks on Redstone. It pays no dividends.
Current Drawdown
-32.55%
Rolling Volatility
77.17%
Actions
Metrics
Risk Indicators
Alpha41.28%
Beta1.68x
Sharpe0.72
Sortino1.19
Omega1.13
Calmar0.78
Martin2.59
Profile
About CCCC
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives.
- Sector
- Health Care
- Industry
- Biological Products, (no Diagnostic Substances)
- Market cap
- $388M
- Listed
- Oct 2020
- Employees
- 104
- Headquarters
- Watertown, MA
- Website
- c4therapeutics.com
Comparisons